Journal of Alzheimers & Neurodegenerative Diseases Category: Clinical Type: Review Article

NLRP3 Inflammasome and Alzheimer's Disease

Li Fan1, Jin Suqin1, Xu Feng1* and Xie Zhaohong1*
1 Department of neurology, The Second Hospital, Cheeloo College of Medicine, Shandong University, 247 North Park Avenue, Jinan 250033, China

*Corresponding Author(s):
Xu Feng
Department Of Neurology, The Second Hospital, Cheeloo College Of Medicine, Shandong University, 247 North Park Avenue, Jinan 250033, China
Tel:+86 531 85875443,
Xie Zhaohong
Department Of Neurology, The Second Hospital, Cheeloo College Of Medicine, Shandong University, 247 North Park Avenue, Jinan 250033, China
Tel:+86 531 85875443,

Received Date: Jul 24, 2020
Accepted Date: Jul 31, 2020
Published Date: Aug 07, 2020


NLRP3 inflammasome is an important part of the innate immune system and mediates inflammatory responses and pyroptosis. A two-signal model of NLRP3 inflammasome activation has been proposed. Ionic flux?lysosomal damage?reactive oxygen species and mitochondrial dysfunction have been shown to activate the NLRP3 inflammasome. The regulating mechanism of the NLRP3 inflammasome include post-translational modifications of NLRP3 and interacting partners. Recently, Nek7 has been identified as a critical NLRP3 regulator. NLRP3 inflammasome is closely related to the occurrence and development of neuroinflammation in Alzheimer's disease. NLRP3 inflammasome is closely related to the occurrence and development of Alzheimer's disease neuroinflammation and is considered as a new target for the treatment of Alzheimer's disease.


NLRP3 inflammasome; Alzheimer's disease


PRRs: Pattern-recognition receptors

PAMP: Pathogen-associated molecular pattern

DAMP: Damage-associated molecular pattern

NLRNOD: Like receptor

ASC: Apoptosis-associated speck-like protein contain a CARD

AIM2: Absent-in-melanoma 2

GSDMD: Gasdermin-D

TLRs: Toll-like receptors

ROS: Reactive oxygen species

P2X7P2X: Ligand-gated ion channel 7

TXNIP: Thioredoxin-interacting protein

TRX: Thioredoxin

NOX2: NADPH oxidase 2

NOX4: NADPH oxidase 4

CPT1: Acarnitine palmitoyltransferase 1A

MAM: Mitochondrial binding endoplasmic reticulum membrane

MAVS: Mitochondrial antiviral-signaling protein

PKR: Double-stranded RNA dependent protein kinase

GBP5: Guanylate binding protein 5

AP2: Aminopurine

NIMA: Never-in-mitosis A

shRNA: Short hairpin RNA

DAPPDN: N′-diacetyl-p-phenylenediamine


Alzheimer's disease (AD) is the main cause of dementia and constitutes a major public health problem as the world’s population is aging. At present, the etiology and pathogenesis of AD are still not very clear, and there is no specific treatment for AD. Recent studies have shown that persistent inflammation plays an important role in the pathophysiological mechanism of AD. NLRP3 Inflammasome plays a critical role in the inflammatory response in AD. In this article, we reviewed the mechanisms of NLRP3 inflammasome activation and regulation, and progress in targeting NLRP3 in the AD therapy.


Pattern-recognition receptors (PRRs) is a specific protein in innate immune system that recognizes foreign stimuli and feels damage from the internal body [1]. PRRs recognize specific microbial components which is named pathogen-associated molecular pattern (PAMP) or damage associated molecular pattern (DAMP). NOD-like receptor (NLR) is an intracellular PRR which can recruit pro-caspase-1, the precursor of caspase-1, directly or through apoptosis-associated speck-like protein contain a CARD (ASC), and then forms a protein complex called the inflammasome. NLR family members NLRP1, NLRP3 and NLRC4 have been confirmed to form inflammasomes as well as absent-in-melanoma 2 (AIM2) and pyrin [2,3]. The NLRP3 inflammasome has been the most intensively investigated inflammasome in the past decade. The assembly of inflammasome can activate pro-caspase-1 and produce caspase-1 with enzymatic activity, which further processes the precursors of the inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL -18) into mature IL-1β and IL -18. These cytokines are secreted extracellularly, and finally play a proinflammatory role. NLRP3 inflammasome also mediates a caspase-1 dependent cell death which is called pyroptosis. Gasdermin-D (GSDMD) protein is the executor of pyroptosis. Activated Caspase-1 specifically cleaved GSDMD into the N-terminal domain and the C-terminal domain. The lipophilic GSDMD-N-terminal domain forms oligomers and result in the occurrence of cell pyrolysis [4].


It has been suggested that NLRP3 inflammasome activation requires two signals: priming and activation. Priming signal conferred by stimulation such as ligands for toll-like receptors (TLRs) activates NF-κB pathway which then upregulates the expression of NLRP3 and pro-IL-1β [5,6]. Following the priming step, a lot of stimuli including ATP, K+ ionophores [7], particulate matter [8,9], pathogen-associated RNA [10] can active NLRP3. Activation of NLRP3 induces multiple molecular and cellular signaling events including ionic flux, mitochondrial dysfunction and the production of reactive oxygen species (ROS), and lysosomal damage?which have been shown to activate the NLRP3 inflammasome.

NLRP3 stimuli induce ionic flux events including K+ efflux, Ca2+ mobilization, Na+ influx and Cl- efflux. High concentration of ATP released during cell injury or necrosis can bind to purine receptor P2X ligand-gated ion channel 7(P2X7), leading to rapid outflow of potassium (K+) and activation of NLRP3 inflammasome [11]. Recent studies have found that several small chemical compounds, including imiquimod?GB111-NH2, and CL097 were able to activate NLRP3 independently of potassium efflux [12,13]. Some studies suggest Ca2+ mobilization were involved in NLRP3 inflammasome activation, but how the increase in cytosolic Ca2+ promotes NLRP3 inflammasome activation remains unclear [14,15]. One study suggests that increase of Ca2+ can promote interaction between NLRP3 and ASC in cell lysates of macrophages thereby directly regulates NLRP3 inflammasome activation [16]. Most studie suggest Ca2+ mobilization might not be essential for NLRP3 inflammasome activation [17]. Na+ influx and Cl- efflux play a regulatory role in NLRP3 inflammasome activation related to the potassium ion flow. Some PAMPs, such as larger particles, crystals or living pathogens, can destabilize the phagocytes and disrupt lysosomal membranes, leading to the release of cathepsin B into the cytoplasm and the activation of NLRP3 inflammasomes [18]. However, after inhibiting acid-dependent lysosomal proteases with proton pump inhibitors, the activation of NLRP3 inflammatome induced by crystallization was almost completely inhibited, confirming the important role of lysosomal injury in the activation of NLRP3 inflammatome. Lysosomal rupture leads to release of several components such as cathepsin G, cathepsin B and then activates the NLRP3 inflammasome [19].

ROS is considered to be a common signal of activation of NLRP3 inflammosome. Thioredoxin-interacting protein (TXNIP) is a ligand for NLRP3 and is sensitive to ROS. Under normal physiological conditions, the oxidoreductase thioredoxin (TRX) binds to TXNIP and inhibits its activity; when the intracellular ROS concentration increases, the complex dissociates, TXNIP and NLRP3 (mainly LRRs domains) combined to activate NLRP3 [20]. Recently, a study showed that the deletion of superoxide generating NADPH oxidase 2 (NOX2) reduces the expression of NLRP3 in a model of traumatic brain injury, which disrupts NLRP3-TXNIP interaction in the cerebral cortex of mice after ischemic stroke, but not in umbilical vein endothelial cells, suggesting that role of ROS in activation of NLRP3 inflammasome have tissue specificity [21]. Another reseach found that NADPH oxidase 4 (NOX4) could regulate carnitine palmitoyltransferase 1A (CPT1A) and cause increased fatty acid oxidation, which contributes to NLRP3 inflammasome activation [22]. Lysosomal NADPH oxidase was originally thought to be the source of ROS production. But In human peripheral blood monocytes and mouse macrophages that lack NADPH oxidase activity, NLRP3 inflammatory bodies can still be activated normally [23]. Mitochondria are thought to be involved in inflammasome activation as an important source of ROS and interaction with the components of the NLRP3 inflammasome. Research suggests mitochondrial dysfunction and mtROS production are dispensable in NLRP3 inflammasome activation [24]. NLRP3 inflammasome mediated IL-1β secretion is affected by cytoplasmic and mitochondrial ROS levels and mitochondrial function [25]. A reaserch fiound that mtROS can stimulate the relocation of NLRP3 from the endoplasmic reticulum to the mitochondrial binding endoplasmic reticulum membrane (MAM). At the same time, ASC is also recruited from the cytoplasm to the MAM, and it is sequentially combined with NLRP3 and pro-caspase-1 to assemble the NLRP3 Inflammasome [26]. Some research found oxidized mtDNA is required for NLRP3 inflammasome activation [27]. Besides the generation of mtROS and mtDNA, some mitochondrial molecules are associated with NLRP3, such as mitochondrial antiviral-signaling protein (MAVS),mitofusin 2 and cardiolipin [28,29]. Taken together, mitochondrial function plays an important role in the activation of NLRP3 inflammasome.


NLRP3 inflammasome activation is regulated by several mechanisms. Post-translational modifications of NLRP3 have been identified in regulating NLRP3 such as ubiquitination and phosphorylation. Some NLRP3 Interacting partners, have been reported to regulate the NLRP3 inflammasome, including double-stranded RNA dependent protein kinase (PKR), guanylate binding protein 5 (GBP5), and Nek7.

PKR regulates the activation of all known inflammasome, including NLRP3. It has been evidenced that the activation of Caspase-1 and the secretion of IL-1β and IL-18 were significantly inhibited in in macrophages extracted from PKR-deficient mice; and PKR inhibitor 2-aminopurine (2-AP) could inhibit the activation of Caspase-1 and the production of IL-1β in macrophages derived from wild-type mice [30]. However, the results were not consistent as another study suggested that PKR was not necessary for the activation of inflammasomes, the activation of Caspase-1, the lysis of pro-IL-1β, and the secretion of IL-1β [31]. The role of GBP5 in the activation of NLRP3 inflammasomes is also controversial. When stimulated by ATP, nigericin and bacteria, GBP5 promotes the activation of NLRP3 inflammasome but this effect had not been observed when NLRP3 stimulated by insoluble particulate matter such as MSU or alum [32].

Unlike PKR and GBK5, three research groups have independently found that Nek7 was a critical regulator for NLRP3 inflammasome activation. Nek7 belongs to the NIMA (never-in-mitosis A)-related kinase family and is mainly involved in regulating the mitotic process and DNA damage response. Studies have shown that mice with defects in Nek7 died later in their embryonic development and their growth was blocked, indicating that Nek7 might play a pivotal role in embryo growth and survival [33]. Related studies have suggested that Nek7 was dispensable for NLRP3 inflamasome activation by all kinds of stimuli (including ATP, nigericin, MSU crystals, and alum), while it was not a necessity in the activation of NLRP4 and AIM2 inflammasome [34-36]. The catalytic region of Nek7 binds to the LRR domain of NLRP3 to form a NLRP3-NEK7 macromolecular complex, which is enhanced by NLRP3 agonists. Nek7 can regulate the oligomerization of NLRP3, ASC Speck formation and caspase-1 activation downstream of K+ outflow. Compared with wild-type mice, Nek7-deficient mice have reduced IL-1β secretion, weakened immune cell aggregation, and reduced disease severity, suggesting the important role of Nek7 in NLRP3 activation in in vivo models [34,35]. However, more researches are needed to determine the mechanism by which Nek7 regulates NLRP3 inflammasome activation.


Microglia play an important role in Aβ clearance and neuroinflammatory response, and microglia-mediated inflammation has been a focus of AD researches. Recent studies have found that microglia can express NLRP3, ASC and Caspase-1 [37]. Researchers first reported in 2008 that NLRP3 inflammasomes were activated after incubating primary microglia in mice with Aβ, and microglia phagocytosis of fibrotic Aβ resulted in lysosome rupture to promote the secretion of inflammatory cytokines including IL-1 [38], which could has been proved to activate NLRP3 inflammasome [39]. NLRP3 inflammasome activation can promote Aβ deposition and the pathological process of AD in the brains of APP/PS1 transgenic mice, while NLRP3 or Caspase-1 gene knockout can regulate the microglia phenotype of APP/PS1 transgenic mice, enhance their phagocytic ability, and improve Aβ deposition and behavioral abnormalities; Specifically knockdown of NLRP3 or Caspase-1 in microglia transformed microglia into the M2 phenotype, presenting as an increased clearance and spatial memory [40]. Systemic inflammation reduced microglial clearance of Aβ in APP/PS1 mice through NLRP3 inflammasome and NLRP3 inflammasome knockout blocked microglial changes upon lipopolysaccharide, including alterations in microglial morphology and amyloid pathology [41]. Intrahippocampal injection of ASC specks resulted in spreading of Aβ pathology in transgenic double-mutant APP/PS1 mice, supporting the concept that inflammasome activation is connected to seeding and spreading of Aβ pathology in patients with Alzheimer's disease [42]. NLRP3 inflammasome can be activated not only by fibrillar Aβ aggregates, but also by lower molecular weight Aβ oligomers and protofibrils. Besides Aβ pathology, tau protein has been shown to activate the NLRP3 inflammasome in microglia and its oligomerization was exacerbated by ASC similar to Aβ plaques [43]. Another study showed that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner [44].

Further studies have shown that Aβ can induce cortical neuron pyrolysis, and Caspase-1 short hairpin RNA (shRNA) has the effect of reducing neuropyrolysis in brain tissue of APP/PS1 transgenic mice and improving behavioral abnormalities [45]. NLRP3 inflammasome Inhibitor can reduce the microglia pyrolysis of APP/PS-1 transgenic mouse and promote Aβ clearance. A recently study found that Aβ1-42 could induce pyrolysis by GSDMD protein, and NLRP3-caspase-1 signaling pathway was important to initiate GSDMD cleavage, which plays an important role in Aβ1-42-induced pyrolysis in neurons [46]. These studies suggested that the pyrolysis mediated by inflammasome may be involved in the pathogenesis of AD.

Due to the important role of NLRP3 inflammasome in AD, progresses have been made in the development of therapeutics that target the NLRP3 inflammasome and its associated pathways. So far, several specific NLRP3 inflammasome inhibitors have been confirmed, including MCC950, JC-124, CY-09, OLT1177, Tranilast and Oridonin, some of which been found to help ameliorate AD pathology in animal experiments. MCC950 was proved to reduce the accumulation of Aβ in the brain tissue of APP/PS1 transgenic mice and improve their behavioral abnormalities [47]. JC-124 was found to ameliorate Aβ deposition and reduce the level of Aβ1-42 in the brain of CRND8 mice which was accompanied by reduced β-cleavage of APP, reduced activation of microglia but enhanced astrocytosis [48]. Oridonin can inhibit glial activation, decrease the release of inflammatory cytokines, inhibit NF-κB pathway and Aβ1-42-induced apoptosis in the hippocampus of AD mice model [49]. A study found that a small synthetic molecule N,N′-diacetyl-p-phenylenediamine(DAPPD) , was able to promote the phagocytic aptitude of microglia and subsequently ameliorate cognitive defects by suppressing the expression of NLRP3 inflammasome- associated proteins through its impact on the NF-κB pathway [50].

Some drugs, which have been shown to inhibit the NLRP3 inflammasome, are found to play a protective role in AD. Edaravone, a commonly used drug ischemic cerebrovascular disease, has been proved to attenuates the proinflammatory response in Aβ-treated microglia by inhibiting NLRP3 Inflammasome-mediated IL-1β secretion [51]. Another drug used for ischemic cerebrovascular disease, Dl-3-n-butylphthalideis, has also been found to exert protective effect in APP/PS1 transgenic mice by inhibiting the activation of NLRP3 inflammasome [52]. Progesterone, a neuroactive steroids, can significantly inhibit Aβ-induced NLRP3-Caspase-1 inflammasome activation and play a protective role in AD [53]. Choline supplementation could improve behavioral deficits and pathology in APP/PS1 mice through inhibition of NLRP3 inflammasome activation and restoration of synapse membrane formation [54]. Artemisinin inhibits the activation of NF-κB and NLRP3 inflammasome and reduces Aβ deposition in the brain tissue and neuroinflammation of APP/PS1 transgenic mice [55]. A recently study found gut microbiota in AD patients could induce the activation of NLRP3 inflammasome in the intestinal tract of mice, which could causing the subsequently release of inflammatory factors. The inflammatory factors could further aggravate the inflammation in the nervous tissue and activation of microglia through the intestinal tract. This study suggested a novel idea of AD treatment by improving the composition of gut microbiota [56].


NLRP3 inflammasome plays an important role in the neuroinflammatory response associated with AD. Although the NLRP3 inflammasome has been the most intensively investigated inflammasome in the past decade, a unified mechanism for NLRP3 inflammasome activation has not been determined. Recently, Nek7 is identified as a critical NLRP3 regulator. Regardless of the complexity of the pathway, many molecules and drugs targeting the NLRP3 inflammasome have been discovered, providing a new direction for the treatment of AD. The activation/inhibition mechanism of NLRP3 inflammasome and its regulation of the functional state of brain microglia and the pathophysiological process of Alzheimer's disease remain to be further studied. Further clinical trials are necessary to confirm the role of NLRP3 inhibitors in AD.Research on the neuroinflammation mechanism in AD is beneficial to the prevention, treatment and management of AD patients [57].


Xie Zhaohong and Xu Feng conceived the review; Li Fan and Jin Suqin discussed and contributed to the writing of this review.


This work was supported by the Fundamental Research Funds of Chinese Academy of Medical Sciences (2019-RC-HL-026).Shandong University Multidisciplinary Research and Innovation Team of Young Scholars (2020QNQT019), the National Natural Science Foundation of China (81870848).


  1. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140: 805-820.
  2. Sharma D, Kanneganti TD (2016) The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. J Cell Biol 213: 617-629.
  3. Lamkanfi M, Dixit VM (2014) Mechanisms and unctions of Inflammasomes. Cell 157: 1013-1022.
  4. Shi J, Gao W, Shao F (2017) Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci 42: 245-254.
  5. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, Donald KM, et al. (2009) Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression. J Immunol 183: 787-791.
  6. Franchi L, Eigenbrod T, Núñez G (2009) Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation. J Immunol 183: 792-796.
  7. Mariathasan S, Weiss DS, Newton K, Bride JM, Rourke KO, et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
  8. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, et al. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
  9. Dostert C, Pétrilli V, Bruggen RV, Steele C, Mossman BT, et al. (2008) Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica. Science 320: 674-677.
  10. Eigenbrod T, Dalpke AH (2015) Bacterial RNA: An Underestimated Stimulus for Innate Immune Responses. J Immunol 195: 411-418.
  11. Deplano S, Cook HT, Russell R, Franchi L, Schneiter S, et al. (2013) P2X7 receptor-mediated Nlrp3- inflammasome activation is a genetic determinant of macrophage-de- pendent crescentic glomerulonephritis. J Leukoc Biol 93: 127-134.
  12. Groß CJ, Mishra R, Schneider KS, Medard G, Wettmarshausen J, et al. (2016) K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria. Immunity 45: 761-773.
  13. Sanman LE, Qian Y, Eisele NA, Ng MT, Linden WAV, et al. (2016) Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death. eLife 5: e13663.
  14. Clapham DE (2007) Calcium signaling. Cell 131: 1047-1058.
  15. Murakami T, Ockinger J, Yu J, Byles V, Mccoll A, et al. (2012) Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci USA 109: 11282-11287.
  16. Lee GS, Subramanian N, Kim AI, Aksentijevich I, Mansky RG, et al. (2012) The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492: 123-127.
  17. Katsnelson MA, Rucker LG, Russo HM, Dubyak GR (2015) K+ Efflux Agonists Induce NLRP3 Inflammasome Activation Independently of Ca2+ Signaling. J Immunol. 194: 3937-3952.
  18. Rubartelli A (2010) Redox control of NLRP3 inflammasome activation in health and disease. J Leukoc Biol 92: 951-958.
  19. Hornung V, Bauernfeind F, Halle A (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
  20. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140.
  21. Ma MW, Wang J, Dhandapani KM, Brann DW (2017) NADPH Oxidase 2 Regulates NLRP3 Inflammasome Activation in the Brain after Traumatic Brain Injury. Oxid Med Cell Longev 2017: 6057609.
  22. Moon JS, Nakahira K, Chung KP, Denicola GM, Koo MJ, et al. (2016) NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat Med 22: 1002-1012.
  23. Van BR, Köker MY, Jansen M, Houdt M, Roos D, et al. (2010) Human NLRP3 inflammasome activation is Nox1-4 independent. Blood 115: 5398-5400.
  24. Planillo RM, Kuffa P, Colón GM, Smith BL, Rajendrian TM, et al. (2014) K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38: 1142-1153.
  25. Jabaut J, Ather JL, Taracanova A, Poynter ME, Ckless K (2013) Mitochondria-targeted drugs enhance Nlrp3 inflammasome dependent IL-1β secretion in association with alterations in cellular redox and energy status. Free Radic Biol Med 60: 233-245.
  26. Zhou R, Yazdi AS, Menu P (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225.
  27. Shimada K, Crother TR, Karlin J, Dagvdorz J, Chiba N, et al. (2012) Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis. Immunity 36: 401-414.
  28. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nuez G, et al. (2011) Cutting edge: Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 187: 613-617.
  29. Park S, Juliana C, Hong S, Datta P, Hwang I, et al. (2013) The mitochondrial anti-viral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol 191: 4358-4366.
  30. Lu B, Nakamura T, Inouye K, Li J, Tang Y, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-674.
  31. He Y, Franchi L, Nunez G (2013) The protein kinase PKR is critical for LPSinduced iNOS production but dispensable for inflammasome activation in macrophages. Eur J Immunol 43: 1147-1152.
  32. Shenoy AR, Wellington DA, Kumar P, Kassa H, Booth CJ, et al. (2012) GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 336: 481-485.
  33. Salem H, Rachmin I, Yissachar N, Cohen S, Amiel A, et al. (2010) Nek7 kinase targeting leads to early mortality, cytokinesis disturbance and polyploidy. Oncogene 29: 4046-4057.
  34. He Y, Zeng MY, Yang D, Motro B, Nunez G (2016) NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530: 354-357.
  35. Shi H, Ying W, Li X, Zhan X, Tang M, et al. (2016) NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol 17: 250-258.
  36. Schmidburgk JL, Chauhan D, Schmidt T, Ebert TS, Reinhardt J, et al. (2016) A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J Biol Chem 291: 103-109.
  37. Gustin A, Kirchmeyer M, Koncina E, Felten P, Losciuo S, et al. (2015) NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS One10: E0130624.
  38. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppien A (2008) Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer’s pathology. J Cell Mol Med 12: 2255-2262.
  39. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, et al. (2008) The NALP3 inflammasome is in volved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865.
  40. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, et al. (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-678.
  41. Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, et al. (2019) Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome. EMBO J 38: e101064.
  42. Venegas C, Kumar S, Bernardo S, Franklin BS, Dierkes T, et al. (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. Nature 552: 355-361.
  43. Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, et al. (2019) Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathologica 137: 599-617.
  44. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, et al. (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575: 669-673.
  45. Tan MS, Tan L, Jiang T, Zhu XC, Wang HF, et al. (2014) Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Dis 5: E1382.
  46. Han C, Yang Y, Guan Q, Zhang X, Shen H, et al. (2020) New mechanism of nerve injury in Alzheimer’s disease: β-amyloidinduced neuronal pyroptosis. J Cell Mol Med 24: 8078-8090.
  47. Dempsey C, Araiz AR, Bryson KJ, Finucane O, Larkin C, et al. (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun 61: 306-316.
  48. Yin J, Zhao F, Chojnacki JE, Fulp J, Klein WL, et al. (2018) NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease. Mol Neurobiol 55: 1977-1987.
  49. Wang S, Yang H, Yu L, Qian L, Zhao H, et al. (2014) Oridonin attenuates Abeta1-42-induced neuroinflammation and inhibits NF-kappaB pathway. PLoS ONE 9: e104745.
  50. Park MH, Lee M, Nam G, Kim M, Kang J, et al. (2019) N, N'-Diacetyl-p-phenylenediamine restores microglial phagocytosis and improves cognitive defects in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 116: 23426-23436.
  51. Wang HM, Zhang T, Huang JK, Xiang JY, Chen JJ, et al. (2017) Edaravone Attenuates the Proinflammatory Response in Amyloid-beta-Treated Microglia by Inhibiting NLRP3 Inflammasome-Mediated IL-1beta Secretion. Cell Physiol Biochem 43: 1113-1125.
  52. Wang CY, Xu Y, Wang X, Guao C, Wang T, et al. (2019) Dl-3-N-butylphthalide inhibits NLRP3 inflammasome and mitigates Alzheimer's-like pathology via Nrf2-TXNIP-TrX axis. Antioxid Redox Signal 30: 1411-1431.
  53. Honga Y, Liub Y, Yu D, Wang M, Hou Y, et al. (2019) The neuroprotection of progesterone against Aβ-induced NLRP3-Caspase-1 inflammasome activation via enhancing autophagy in astrocytes. International Immunopharmacology 74: 105669.
  54. Wang Y, Guan X, Chen X, Cai Y, Ma Y, et al. (2019) Choline Supplementation Ameliorates Behavioral Deficits and Alzheimer’s Disease-Like Pathology in Transgenic APP/PS1 Mice. Mol Nutr Food Res 63: e1801407.
  55. Shi JQ, Zhang CC, Sun XL, Cheng XX, Wang JB, et al. (2013) Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-κB and NLRP3 inflammasome activation. CNS Neurosci Ther 19: 262-268.
  56. Shen H, Guan Q, Zhang X, Yuan C, Tan Z, et al. (2020) New mechanism of neuroinflammation in Alzheimer's disease: The activation of NLRP3 inflammasome mediated by gut microbiota. Prog Neuropsychopharmacol Biol Psychiatry 100: 109884.
  57. Tai Yu, Wei Xu, Tan CC, Andrieu S, Suckling J, Evangelou E, et al. (2020) Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry.

Citation: Fan L, Suqin J, Feng X, Zhaohong X (2020) NLRP3 Inflammasome and Alzheimer's Disease. J Alzheimer’s Neurodegener Dis 6: 045.

Copyright: © 2020  Li Fan, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Sciences. Our mission is to provide an access to knowledge globally.

© 2023, Copyrights Herald Scholarly Open Access. All Rights Reserved!